Followers | 1321 |
Posts | 26906 |
Boards Moderated | 6 |
Alias Born | 12/10/2012 |
Thursday, June 29, 2023 9:13:11 AM
Booooooooooooyakashaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
Immunome and Morphimmune Announce Definitive Merger Agreement and Simultaneous Private Placement Investment of $125 Million to Develop Targeted Cancer Therapies
GO $IMNM
Recent IMNM News
- Immunome Appoints Kinney Horn as Chief Business Officer • Business Wire • 05/02/2024 12:00:00 PM
- Immunome Appoints Sandra M. Swain to Board of Directors • Business Wire • 04/25/2024 12:26:00 PM
- Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting • Business Wire • 04/05/2024 12:00:00 PM
- Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets • Business Wire • 03/28/2024 08:02:00 PM
- Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala • Business Wire • 03/26/2024 12:00:00 PM
- Immunome to Participate in the Leerink Partners Global Biopharma Conference • Business Wire • 03/07/2024 01:00:00 PM
- Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference • Business Wire • 03/01/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 02:10:50 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 02:07:36 AM
- Immunome Recognizes Ayala Pharmaceuticals’ Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors • Business Wire • 02/20/2024 01:15:00 PM
- Immunome Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares • Business Wire • 02/16/2024 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 09:11:03 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/14/2024 09:09:03 PM
- Immunome Announces Pricing of Public Offering of Common Stock • Business Wire • 02/14/2024 03:38:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/13/2024 09:36:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 09:10:43 PM
- Immunome Announces Proposed Public Offering of Common Stock • Business Wire • 02/13/2024 09:05:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/12/2024 07:10:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2024 01:05:29 PM
- Immunome to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference • Business Wire • 02/05/2024 01:00:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/02/2024 09:04:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/01/2024 01:53:57 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/01/2024 01:50:43 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/11/2024 10:27:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 12:05:49 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM